asdsd

1. 2015 Opportunities and
Outlook for Growth
Human & Animal Health

2. OTC:ZIVO.QB
Notice to Investors & Analysts
This Business Summary, Investment Summary and any Exhibits to it
contain forward-looking statements that involve risks and uncertainties.
These statements reflect the Company’s future plans, objectives,
expectations and intentions, and the assumptions underlying or relating
to any of these statements. These statements may be identified by the
use of the words “anticipate,” “expect,” “estimate,” “intend,” “believe,”
and similar expressions. The Company’s actual results could differ
materially from those discussed in these statements. Factors that could
contribute to these differences include, but are not limited to, those
discussed in this document.
Screen #2

3. Overview
ZIVO Bioscience (formerly Health Enhancement Products, Inc.)
holds valuable intellectual property in the form of bioactive
compounds that promise to:
 Support a healthy immune response in animals and humans
 Promote healthy cholesterol balance in humans
 Support joint health in animals and humans
 Applications in food ingredients, dietary supplements, pharma
Screen#3

4. Speed to Revenue
The company intends to drive near-term revenue by monetizing animal
nutrition and health market verticals while we continue to develop
longer-range products that represent larger opportunities, such as
human therapeutic agents
 After efficacy/safety testing and registration, the Company’s natural
animal products may be monetized in a matter of months by licensing
to larger, well-established brand names as healthy feed and pet treat
ingredients
 Company is validating and intends to license its bioactive compounds
to animal health companies for future therapeutic use
 Human product development/compliance as a dietary supplement
starts once revenue streams from animal licenses are realized
 Company spreads development risk and capital across feed, food,
dietary supplement, medicinal and pharma market verticals, while
sprinting toward positive cash flow
Monetizing Multiple Verticals
Screen #4

5. Market Potential Animal Health
The Company’s proprietary, algae-derived bioactive compounds are
found to be effective in early studies when applied to dairy cattle
and dog models – our highest near-term priorities
 Accelerate recovery from bovine mastitis – potentially saving
US dairy farmers $2.8+ billion in lost milk production annually.
The world’s 244 million dairy cows represent an untapped market
 Have been shown to slow the degenerative effects of canine
osteoarthritis – a proven $300 million market in the US alone
 Company has already executed a Collaboration/Option
agreement with world’s largest animal health company for
bovine mastitis research
Near-Term Opportunities
Screen #5

6. Research Animal Health
The Company’s proprietary algal culture, its extracts and isolates,
are found to be effective in pre-NDI studies as applied to dairy cattle
and dog models
 In-vitro testing of primary bovine mammary epithelial cells in 3D
culture at University of Wisconsin-Madison Dept. of Dairy Science
indicated enhanced immune response when cells were exposed to
infective pathogens responsible for bovine mastitis, 2013-2014
 Explant testing of canine joint tissues at University of Missouri
Comparative Orthopaedic Laboratory has indicated the Company’s
bioactive compounds may slow the degenerative effects of canine
osteoarthritis in early 2014
 Dairy cow mastitis in vivo pilot study at UC-Davis yielded very
impressive results in combatting mycoplasma bovis. Company is
currently negotiating option with Zoetis, formerly Pfizer Animal
Health – world’s largest animal pharma company
Recent Developments
Screen #6

7. Research Bovine Mastitis Study
Recent News
0
1
2
3
4
5
6
7
8
9
10
IMM NO TX SQ ORAL
NumberofAnimals
Abnormal milk
Normal milk
Milk Appearance Scoring
Screen #7

8. IMM Mycoplasma (cfu/ml) NO TX Mycoplasma (cfu/ml) SQ Mycoplasma (cfu/ml) ORAL Mycoplasma (cfu/ml)
356
572153
4181
8212
2248
1283
3299
2
3369
253
1143
1842
1888
2568
2581
3880
3975
42
139
568
1088
1456
1656
2298
2929
3664
68
533
1036
1384
1570
2153
2919
3539
TREATMENT 1 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 0 0 >300 >300 >300 0 >300 >300 >300 >300 0 >300 0 0 >300 >300 >300 0 >300 0
2 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 0 0 >300 >300 >300 0 0 >300 13 >300 >300 >300 CT 0 >300
3 >300 >300 >300 >300 300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 2 300 >300 >300 >300 >300 >300 0 >300 >300 >300 >300 0 >300 >300 >300 >300 >300 >300
4 0 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 16 0 >300 >300 >300 >300 0 >300 >300 >300 >300 0 >300 >300 >300 30 >300 >300
5 >300 >300 0 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 0 >300 >300 >300 >300 >300 0 >300 >300 >300 >300 >300 0 >300 >300 >300 >300 >300 >300
6 >300 >300 >300 0 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 300 >300 >300 >300 >300 0 0 >300 >300 >300 >300 0 >300 >300 >300 >300 >300 >300
7 >300 >300 >300 >300 >300 >300 >300 300 120 >300 >300 CT 100 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 0 >300 >300 >300 NS >300 >300
8 >300 >300 >300 >300 >300 >300 20 200 50 >300 >300 >300 200 >300 100 300 75 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 0 >300 >300 >300 >300 >300 300
POST-TREATMENT
9 >300 50 >300 >300 >300 >300 170 >300 200 >300 >300 >300 300 >300 >300 >300 300 >300 >300 >300 >300 300 >300 >300 >300 >300 >300 0 >300 >300 >300 NS >300 >300
10 >300 45 >300 >301 >300 >300 >300 50 >300 300 >300 0 >300 >300 NS >300 55 >300 >300 >300 300 >300 >300 >300 >300 >300 >300 0 200 >300 300 >300 >300 200
11 15 42 0 0 300 >300 150 100 >300 >300 >300 300 >300 >300 100 >300 16 4 >300 >300 200 0 >300 >300 >300 >300 300 0 >300 >300 >300 >300 >300 >300
12 >300 0 0 0 >300 >300 >300 >300 >300 >300 >300 300 >300 NS >300 >300 1 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 0 >300 >300 100 300 >300 >300
13 300 0 >300 300 250 300 300 >300 NS 300 300 >300 >300 >300 >300 >300 0 270 >300 300 100 >300 100 300 >300 >300 >300 0 >300 >300 300 >300 300 2
14 0 0 >300 >300 200 >300 >300 >300 NS >300 >300 >300 >300 >300 >300 >300 7 >300 >300 >300 0 >300 200 >300 >300 >300 >300 0 300 >300 250 >300 >300
15 >300 0 >300 200 0 200 39 >300 NS 200 300 200 >300 NS 300 75 0 >300 >300 >301 5 >300 >300 200 >300 >300 0 0 200 >300 >300 >300 >300 NS
16 170 0 >300 >300 0 0 >300 >300 NS 250 >300 200 >300 >300 300 300 6 100 0 100 3 0 300 0 >300 >300 300 0 >300 >300 300 300 >300 NS
17 200 0 >300 >300 0 65 >300 >300 NS >300 >300 190 >300 >300 0 200 0 0 >300 300 0 0 0 120 >300 >300 300 0 >300 >300 170 >300 >300 >300
18 0 0 >300 300 300 14 >300 >300 NS 200 >300 >300 >300 >300 >300 >300 0 300 >300 170 0 0 0 >300 >300 >300 >300 0 300 >300 250 >300 >300 >300
19 60 0 >300 0 300 25 >300 >300 NS >300 >300 200 >300 >300 35 >300 0 150 >300 300 0 4 200 >300 >300 >301 200 0 >300 >300 200 >300 >300 >300
20 17 0 300 200 >300 0 >300 150 NS NS >300 >300 >300 NS 0 >300 0 43 300 300 0 300 90 >300 >300 >300 >300 0 >300 >300 75 >300 250 >300
21 150 0 >300 0 0 0 >300 150 NS 300 >300 >300 >300 >300 0 >300 0 300 0 300 0 >300 >300 >300 >300 >300 >300 0 >300 >300 13 >300 >300 >300
22 15 0 >300 90 45 2 >300 >300 NS NS >300 80 >300 >300 NS >300 0 81 >300 300 0 >300 300 >300 >300 >300 300 0 150 >300 5 >300 >300 >300
Mycoplasma Presence in CultureScreen #8

9. Research Bovine Mastitis Study
Notable Findings
o Trend for improved milk appearance (color and consistency)
in the intra-mammary (IMM) treatment group
o By study end, 7 out of 9 IMM-treated animals (78%) had
normal milk appearance vs. the non-treated group, which
had 1 out of 8 animals with normal milk production
o There is a trend for IMM group to have considerably fewer
cows infected with mycoplasma pathogen at the end of the
study period compared to non-treated group
Screen #9

10. Licenses/Joint-Ventures
Animal Feed & Health Ingredients
NATURAL PRODUCTS
SYNTHETIC COMPOUNDS
Bovine Feed
Bovine Mastitis pharma
The Company expects to execute licenses as shown. Timeline “0” is close of funding
0 6 months 12 months 18 months
Canine Supplement
Canine Food
MORE REGULATED MORE REGULATED
Canine OA pharma
NATURAL PRODUCTS
Bovine Supplement (Non-US)
Canine Collaboration
Option Agreement
Partner TBD
HIGHLY
REGULATED
LESS
REGULATED
Bovine Collaboration
Option Agreement
Signed Dec. 20, 2013
Screen #10

11. Market Potential Human Health
The Company’s algal biomass, secondary metabolites and extracts
may be developed into ingredients for these market verticals
• Dietary Supplement/Nutraceutical – a $28 billion US
and worldwide market that includes spirulina, algae-derived
Omega-3s, algae-derived astaxanthin, dried kelp, etc.
• Functional Food Ingredient – over 400 good-for-you food
and beverage categories need powerful ingredients to support
their product claims – dozens of licenses can be created
Refined isolates and bioactive molecules for therapeutic applications
• Medical Food – a specialized but stable and profitable market
niche for ingredients in prescribed foods and beverages
• Pharmaceuticals – as potential lead compounds for drug
development
Natural Products/Future Therapeutics
Screen #11

12. Research Human Health
The Company’s proprietary algal culture extracts were found to be
beneficial in pre-NDI/pre-IND studies as applied to human and
hamster models
 In-vivo testing of hypercholesterolemia at Wayne State University
Dept. of Nutrition and Food Science found test subjects treated
with culture extracts dropped total cholesterol by 32% and
increased HDL cholesterol counts by 5% in studies conducted
2009-2012
 In-vitro testing of human HEP-G2 and PBMC cell lines revealed
early promise in addressing inflammatory cascades resulting from
lipid peroxidation in repeated studies at Wayne State University
School of Medicine conducted 2010-2012
 Company conducted isolation and characterization efforts of
bioactive components in 2014 as funding permitted
Natural Products/Future Therapeutics
Screen #12

13. Licenses/Joint-Ventures
Human Nutrition & Health Products
BIOPHARMACOLOGICAL OR
SYNTHETIC COMPOUNDS
Cholesterol Balance
Autoimmune Modulation
The Company expects to execute licenses as shown. Timeline “0” is close of funding
0 12 months 18 months 24 months
Cholesterol Balance
Joint Health
Immune Response
NATURAL PRODUCTS
Joint Health
Human Nutrition
Ingredient JV or
License
PHARMA
REGULATIONS
FOOD SAFETY
REGULATIONS
Human Therapeutic
Lead Compound
Option Agreement
Screen #13

14. Business Model
Company builds the value of intellectual property by:
 Validating a specific application, i.e., bovine mastitis feed ingredient,
through safety/tox testing, in vitro and in vivo studies and then
patenting uses, production methods, administration modes
 Creating a valuable dataset for such a specific application, to shrink
risk and development time for a potential licensee, such as an animal
feed manufacturer, dietary supplement marketer, animal health co.
 Executing royalty agreements, joint ventures and licenses to boost
market value and earning power of the intellectual property
Core Business: Monetizing Early Results
Screen #14

15. Prioritized Objectives
Potential Revenue Streams
Near-Term < 24 months
Bovine Feed Ingredient Canine Diet Supplement
Porcine Feed Ingredient Human Diet Supplement
Longer-Term > 24 months and beyond
Bovine Medicinal App Canine Medicinal App
Pharmaceutical Lead Compound
Screen #15

16. Company Snapshot
Publicly traded, fully-reporting since 2003
 New management and $5.25 million new capital infusion over 3 years
beginning January, 2012
 New business model adopted in January 2012 – Company primarily
engaged in R&D and subsequent licensing/JV of Intellectual Property
Actively acquiring intellectual property
 Acquired assets of metabolic testing company August 2013 – WellMetris
subsidiary currently in FDA pre-submission, preparing for market launch
and active partnering, pending capital funding
 Optioned libido-enhancement drug candidate August 2014 – newly formed
Derivlan Bioscience subsidiary to test compounds in Brazil
Company initiates $4.5M capital funding initiative Q4 2014
Trading symbol: OTC:ZIVO.QB
Screen #16

17. Company Snapshot
WellMetris Profile: Pre-clinical screening tool for insurers,
employers and accountable care organizations
Subsidiary Product Pipeline
Point-of-Care Reporting Software
Analyzer Device
Test Cartridge
Cloud-Based Records Management
WellMetrisScreen #17

18. Exit Strategy
ZIVO Bioscience, Inc. is a publicly-traded
Nevada corporation. Once revenue is optimized,
the options to consider are:
 Sell the entire Company to a larger, well
established JV or licensee for a healthy
multiple
 Spin out the revenue-generating licenses or
subsidiaries into another public entity and
conduct an IPO, distribute proceeds to
Company shareholders pro-rata
 Continue to operate the Company in its
current form and develop new applications
from the Company’s proprietary IP
Realizing the Potential
Screen #18
0
1000
2000
3000
4000
5000
6000
7000
8000
Quarterly Revenues in (000)

19. Management
Since taking over in late December of 2011, the new management team has
focused on reorganizing and revitalizing the enterprise:
• Andrew A. Dahl – President & CEO, former Fortune 500 marketing executive
and consultant with 20+ year track record, previously in private consulting
practice
• Philip M. Rice II – Chief Financial Officer, former DeLoitte CPA, former CFO
Stahl’s, 20+ years management consulting, corporate finance and turnaround
• Scott M. Freeman, MD – Chief Science Officer, former COO/Clinical Studies
Director, Onyx Pharmaceuticals with 20+ years in drug development, clinical
trials management, compliance and regulatory affairs
• Amy E. Steffek, Ph.D.,-- Director, Research & Development, with 14+ years
in scientific research experience spanning neurology, cardiology, oncology,
psychiatry, and endocrinology
• Scott Forsberg – Director, Product Development, former Director of R&D for
Solaray and Director of Marketing for Nature’s Way with 20+ year history in
nutrition and supplement industry
Core Team
Screen #19

20. Summary
The Company holds valuable intellectual property that can be
exploited across several market verticals and potentially
dozens of licenses within:
• Functional food/feed ingredients
• Medicinal products and drug development lead compounds
• Health and Wellness products
These distinctly different market verticals substantially increase
the odds that any one market vertical or application may be
successful. Acquiring related IP provides opportunities that
may help mitigate risk and amortize internal resources
Realizing the Potential
Screen #20

21. Healthy Outcomes
ZIVO Bioscience, Inc. is dedicated to the discovery, re-purposing and
development of products and processes that positively impact health
and wellness in humans and animals
Corporate Mission
Screen #21